Circulating Tumor Cell (CTC) Test Cost & Procedure

These cancerous cells in the bloodstream are the metastatic seeds that can leave the main cancerous site and invade other organs. Understanding circulating tumor cells is crucial since the primary cause of cancer death is frequently caused by cancer's secondary dissemination to other sections of the body.

EpCAM protein is recognized and measured by circulating tumor cell (CTC) count, which is produced by epithelial tumor cells. Testing needs to be done before therapy starts and repeatedly while receiving treatment. CTC count may also help with prognosis and treatment efficacy evaluation.

Overview of the illness Prognostic/Treatment Problems

Cutvaryaryby tumor compartment variety; CTC total in whole blood is an autonomous forecaster of progression-free survival and overall survival.

Breast cancer with metastatic disease (MBC): >5 CTCs/7.5 mL of blood

>3 CTCs/7.5 mL of blood: metastatic colorectal cancer

CTC count may be an indication of antidote convincingness.

Preliminary to the beginning of the antidote, a baseline CTC count should be received. Serial CTC count experimenting may be utilized to navigate antidote conclusions and determine prediction.

A one-point-in-time screening test, the CTC blood test.

aid CTC in assessing the efficacy of cancer patients' treatments Testing is done both before and after therapy to help with an early cancer diagnosis.

Search for further uncommon cells

Analyze the ISET-CTC test's usefulness in clinical settings.

What is CTC analysis, or circulating tumor cell analysis?

ISET-CTC Examination

The ISET-CTC Test is not a diagnostic exam but a screening test.

Circulating tumor cells (CTC) serve as a biomarker for predicting the prognosis of cancer in its earliest stages and the efficacy of treatment.

The "amount of CTC" or "CTC count" reveals cancer's stage or risk of malignancy.

Using filtration and conventional cytological microscopy, the "Isolation by SizE of Tumour (ISET) CTC" test,

Summary

Circulating tumor cells (CTCs) are cancer cells that escape from the main tumor and invade the system of peripheral blood circulation, where they cause metastasis. Through liquid biopsy, sensitive CTC detection from clinical samples can be a useful tool for determining the prognosis and diagnosis of cancer. Due to tumor heterogeneity, existing CTC identification technologies mainly rely on biomarker-mediated platforms like magnetic drips, microfluidic chips, or size-sensitive microfiltration, which might lessen detection keenness.